Holen Sie sich die Stockscreener-App
52.18
2.19%
1.12
Handel nachbörslich:
49.33
-2.85
-5.46%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$51.06
Offen:
$50.09
24-Stunden-Volumen:
1.74M
Relative Volume:
2.57
Marktkapitalisierung:
$4.81B
Einnahmen:
$481.30M
Nettoeinkommen (Verlust:
$-585.12M
KGV:
-5.8172
EPS:
-8.97
Netto-Cashflow:
$-492.48M
1W Leistung:
-1.17%
1M Leistung:
-2.99%
6M Leistung:
+22.06%
1J Leistung:
+34.38%
1-Tages-Spanne:
$49.89
$52.19
1-Wochen-Bereich:
$49.84
$53.20
52-Wochen-Spanne:
$34.06
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc (RARE) Q3 2024 Earnings: Revenue S - GuruFocus.com
Ultragenyx: Q3 Earnings Snapshot - San Antonio Express-News
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
Wealth Enhancement Advisory Services LLC Purchases 14,394 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
A Look Ahead: Ultragenyx Pharmaceutical's Earnings Forecast - Benzinga
Trend Tracker for (RARE) - Stock Traders Daily
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by Emerald Mutual Fund Advisers Trust - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Stock Position Trimmed by abrdn plc - MarketBeat
RAREUltragenyx Pharmaceutical Inc. Latest Stock News & Market Updates - StockTitan
What Makes Ultragenyx Pharmaceutical (RARE) an Exciting Investment Opportunity? - Yahoo Finance
Oversold Conditions For Ultragenyx Pharmaceutical (RARE) - Nasdaq
10,904 Shares in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Bought by Pallas Capital Advisors LLC - MarketBeat
Ultragenyx Pharmaceutical (RARE) to Release Earnings on Tuesday - MarketBeat
Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update - GlobeNewswire
Analysts Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Price Target at $85.08 - MarketBeat
How To Trade (RARE) - Stock Traders Daily
Recent 4.1% pullback isn't enough to hurt long-term Ultragenyx Pharmaceutical (NASDAQ:RARE) shareholders, they're still up 70% over 1 year - Yahoo Finance
Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Yahoo Finance
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical - Benzinga
TD Cowen Increases Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $73.00 - MarketBeat
Ultragenyx Pharmaceutical's (NASDAQ:RARE) investors will be pleased with their favorable 70% return over the last year - Simply Wall St
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
Cwm LLC Buys 21,111 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Sees Significant Decline in Short Interest - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $393,853.40 in Stock - MarketBeat
Ultragenyx CFO sells shares worth over $390k By Investing.com - Investing.com South Africa
Ultragenyx CFO sells shares worth over $390k - Investing.com
RARE's Wilson Disease Candidate Betters Standard Therapy in Study - MSN
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag - MSN
Osteogenesis Imperfecta Treatment Market: Global Type, - openPR
Passage Bio Welcomes Tom Kassberg to Board, Aiming to Strengthen Strategic Vision - MSN
Squarepoint Ops LLC Trims Stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx gains FDA breakthrough status for OI drug - Investing.com
FDA grants breakthrough therapy status to Ultragenyx's osteogenesis imperfecta drug - Investing.com
Ultragenyx gains FDA breakthrough status for OI drug By Investing.com - Investing.com South Africa
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta - The Manila Times
Ultragenyx Pharmaceutical's Bone Disease Drug Gets FDA's Breakthrough Therapy Designation - MarketWatch
AQR Capital Management LLC Reduces Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx stock rated Outperform as analyst sees $900M peak sales potential - Investing.com
RARE's Wilson Disease Candidate Betters Standard Therapy In Study - Barchart
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ultragenyx Pharmaceutical Inc-Aktie (RARE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KAKKIS EMIL D | President & CEO |
Sep 03 '24 |
Sale |
55.85 |
20,000 |
1,117,000 |
2,223,985 |
| Huizenga Theodore Alan | SVP, Chief Accounting Officer |
Sep 03 '24 |
Sale |
56.19 |
91 |
5,113 |
41,551 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):